Urotensin II is a potent vasoactive peptide implicated in cardiovascular disease, but clinical trials targeting its receptor have been disappointing despite promising preclinical results, possibly due to complex receptor biology.
Positive preclinical, disappointing clinicalUT receptor antagonists showed clear benefits in animal models of heart failure, pulmonary hypertension, and atherosclerosis, but these results did not translate to human clinical trials — possibly due to complex receptor biology.
What the researchers found
The UT receptor for urotensin II has unexpectedly complex biology that may explain failed clinical translation. Two endogenous ligands — UII and urotensin-related peptide (URP) — bind and activate the receptor differently. The receptor is not restricted to the plasma membrane but also exists intracellularly, potentially inducing different physiological responses. These properties could produce inconsistent but potent vasoactive effects, explaining why UT receptor antagonists showed promise in preclinical models of heart failure, pulmonary hypertension, atherosclerosis, and diabetes but failed to replicate these results in clinical studies.
Why it matters
UII was once considered one of the most exciting targets in cardiovascular peptide pharmacology. Understanding why it failed clinically is important not only for potentially reviving UII-based therapies with better approaches, but also as a cautionary lesson for other peptide drug development programs where complex receptor biology may confound straightforward antagonist strategies.
How the study worked
Narrative review synthesizing preclinical and clinical evidence on urotensin II signaling in cardiovascular disease, with particular focus on receptor pharmacology, ligand binding characteristics, and the discrepancy between preclinical and clinical outcomes.
What this study cannot tell us
As a narrative review, the paper selectively covers the UII literature. The precise reasons for clinical trial failures are speculative based on preclinical observations. The review focuses on cardiovascular applications, though UII has roles in other systems. Some of the receptor biology described (intracellular localization) is based on limited evidence that needs further confirmation.
How to read the evidence
This is a narrative review analyzing the translational gap between preclinical and clinical results for urotensin II. It provides mechanistic hypotheses for clinical failures but does not present new experimental data.
When this study was published
Published in 2019, this review captures a mature assessment of the UII field after clinical disappointments. More recent work may have addressed some of the biological complexities identified here.
The bigger picture
The urotensin II story is a valuable case study in peptide pharmacology: having a potent biological target doesn't guarantee clinical success. As the peptide therapeutics field expands with GLP-1 drugs, CGRP antibodies, and others, understanding what went wrong with UII can help avoid similar pitfalls. The insight about intracellular receptor localization is particularly relevant as more peptide receptors are found to function beyond the cell surface.
Questions still open
- Could biased agonists or antagonists that selectively target specific UT receptor signaling pathways succeed where traditional antagonists failed?
- How does intracellular UT receptor activation differ functionally from surface receptor activation?
- Should future UII-targeted therapies distinguish between UII and URP signaling?
Common questions
What is urotensin II and why was it considered a promising drug target?
Why did drugs targeting urotensin II fail in clinical trials?
Read the original research
Novel insights into the role of urotensin II in cardiovascular disease.
Drug discovery today, 24(11), 2170-2180
Citation
Pereira-Castro, João; Brás-Silva, Carmen; Fontes-Sousa, Ana Patrícia. (2019). Novel insights into the role of urotensin II in cardiovascular disease.. Drug discovery today, 24(11), 2170-2180. https://doi.org/10.1016/j.drudis.2019.08.005